Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab plus ipilimumab compared to ipilimumab alone

被引：1
|
作者：
Postow, Michael Andrew
Kuk, Deborah
Adamow, Matthew
Carrera, Cristina
Wong, Phillip
Curran, Michael A.
Friedman, Claire Frances
Momtaz, Parisa
Shoushtari, Alexander Noor
Wolchok, Jedd D.
Chapman, Paul B.
Callahan, Margaret K.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Hosp Clin Barcelona, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3073
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone
    Hodi, F. Stephen
    Postow, Michael A.
    Chesney, Jason
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Emstoff, Marc S.
    Minor, David R.
    Salama, April
    Taylor, Matthew H.
    Rollin, Linda
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd D.
    CANCER RESEARCH, 2015, 75
  • [2] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Rutkowski, Piotr
    Lao, Christopher D.
    Cowey, C. Lance
    Schadendorf, Dirk
    Wagstaff, John
    Dummer, Reinhard
    Ferrucci, Pier Francesco
    Smylie, Michael
    Butler, Marcus O.
    Hill, Andrew
    Marquez-Rodas, Ivan
    Haanen, John B. A. G.
    Guidoboni, Massimo
    Maio, Michele
    Schoffski, Patrick
    Carlino, Matteo S.
    Lebbe, Celeste
    McArthur, Grant
    Ascierto, Paolo A.
    Daniels, Gregory A.
    Long, Georgina, V
    Bas, Tuba
    Ritchings, Corey
    Larkin, James
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +
  • [3] A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.
    Pili, Roberto
    Adra, Nabil
    Logan, Theodore F.
    Burney, Heather
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy.
    Buchbinder, Elizabeth Iannotti
    Pfaff, Kathleen L.
    Manos, Michael P.
    Ouyang, Olivia
    Ott, Patrick Alexander
    Rodig, Scott J.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
    D'Angelo, Sandra P.
    Larkin, James
    Sosman, Jeffrey A.
    Lebbe, Celeste
    Brady, Benjamin
    Neyns, Bart
    Schmidt, Henrik
    Hassel, Jessica C.
    Hodi, F. Stephen
    Lorigan, Paul
    Savage, Kerry J.
    Miller, Wilson H., Jr.
    Mohr, Peter
    Marquez-Rodas, Ivan
    Charles, Julie
    Kaatz, Martin
    Sznol, Mario
    Weber, Jeffrey S.
    Shoushtari, Alexander N.
    Ruisi, Mary
    Jiang, Joel
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) : 226 - +
  • [6] PKPD relationship of ipilimumab plus nivolumab combination in patients with advanced melanoma
    Goldwirt, L.
    Louveau, B.
    Liv, T.
    Baroudjian, B.
    Allayous, C.
    Da Meda, L.
    Delyon, J.
    Sauvageon, H.
    Lebbe, C.
    Mourah, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 38 - 38
  • [7] Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
    Chen, Jiajia
    Tarantino, Giuseppe
    Severgnini, Mariano
    Baginska, Joanna
    Giobbie-Hurder, Anita
    Weirather, Jason L.
    Manos, Michael
    Russell, Janice D.
    Pfaff, Kathleen L.
    Rodig, Scott J.
    Huang, Amy Y.
    Brennick, Ryan
    Nazzaro, Matthew
    Hathaway, Emma
    Holovatska, Marta
    Manuszak, Claire
    Ranasinghe, Srinika
    Liu, David
    Hodi, F. Stephen
    ONCOIMMUNOLOGY, 2025, 14 (01):
  • [8] Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Chapman, Paul B.
    Jayaprakasam, Vetri Sudar
    Panageas, Katherine S.
    Callahan, Margaret
    Postow, Michael A.
    Shoushtari, Alexander N.
    Wolchok, Jedd D.
    Warner, Allison Betof
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [9] Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery
    Joseph D. Tang
    Matthew N. Mills
    Justyn Nakashima
    Ammoren E. Dohm
    Nikhil I. Khushalani
    Peter A. Forsyth
    Michael A. Vogelbaum
    Evan J. Wuthrick
    Hsiang-Hsuan M. Yu
    Daniel E. Oliver
    James K. C. Liu
    Kamran A. Ahmed
    Journal of Neuro-Oncology, 2024, 166 : 431 - 440
  • [10] Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery
    Tang, Joseph D.
    Mills, Matthew N.
    Nakashima, Justyn
    Dohm, Ammoren E.
    Khushalani, Nikhil I.
    Forsyth, Peter A.
    Vogelbaum, Michael A.
    Wuthrick, Evan J.
    Yu, Hsiang-Hsuan M.
    Oliver, Daniel E.
    Liu, James K. C.
    Ahmed, Kamran A.
    JOURNAL OF NEURO-ONCOLOGY, 2024, 166 (03) : 431 - 440
12345